Kodiak Sciences announced positive Phase III DAYBREAK study results for Zenkuda (tarcocimab tedromer), showing non-inferiority to Regeneron's Eylea in treating wet age-related macular degeneration. The drug demonstrated sustained retinal drying with 54% of patients reaching a six-month dosing interval, superior safety profile, and strong durability. Kodiak plans a multi-indication BLA submission in Q4 2026. The stock surged 178% on the announcement.

Four biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.

A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.

The Russell 2000 small-cap index reached an intraday record high on Friday, capping a 13-day rally—its best run since 2020. The surge was driven by President Trump's announcement of a two-week military pause against Iran, which lowered oil prices and boosted expectations for Federal Reserve rate cuts. Regional banks, industrials, and biotech stocks have led the gains, with the iShares Russell 2000 ETF up 8.6% over two weeks compared to the S&P 500's 1.6% gain.

Several stocks saw significant gains on Thursday, with Ameresco receiving a bullish upgrade from Jefferies, Lithium Americas experiencing potential government interest, and Kodiak Sciences getting an analyst upgrade.

The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.